Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and G-CSF Combination for Patients with Relapsed or Refractory AML

ConclusionOur phase II study preliminary results indicate that the addition of Azacitidene prior to standard therapy can improve the overall response rate and remission status in relapsed/refractory AML. This may provide an opportunity to responding patients to proceed to curative therapy with stem cell transplant.DisclosuresNo relevant conflicts of interest to declare.

Source: Blood - November 21, 2018 Category: Hematology Authors: Motabi, I. H., Iqbal, S., Zaidi, S. Z. A., Albtoosh, B., Alshehry, N. F., AlGhamdi, M. S., Tailor, I. K., Altaf, S. Tags: 613. Acute Myeloid Leukemia: Clinical Studies Source Type: research